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Clinical PerspectiveWhat Is New?Five parameters associated with plaque erosion have been identified: age \<68 years, anterior ischemia, no diabetes mellitus, hemoglobin \>15.0 g/dL, and normal renal function.These parameters indicate that plaque erosion may have different pathophysiology: "non‐traditional" factors including abnormal local fluid dynamics, rather than the traditional vascular inflammation, may play an important role.What Are the Clinical Implications?If these parameters are proven to be predictive of erosion in prospective studies, a subset of acute coronary syndromes patients with high probability of plaque erosion may be easily identified.This subset of patients may be managed conservatively with anti‐thrombotic therapy without invasive procedures.

 {#jah34519-sec-0009}

Plaque erosion is reported to be responsible for about 25% to 40% of patients with acute coronary syndromes (ACS).[1](#jah34519-bib-0001){ref-type="ref"}, [2](#jah34519-bib-0002){ref-type="ref"}, [3](#jah34519-bib-0003){ref-type="ref"} Current guidelines recommend early invasive strategy for all ACS patients except for the low‐risk subgroups[4](#jah34519-bib-0004){ref-type="ref"}, [5](#jah34519-bib-0005){ref-type="ref"} and coronary stents are implanted in the majority of the cases. Recent studies reported that ACS patients with plaque erosion might be treated conservatively without stenting.[6](#jah34519-bib-0006){ref-type="ref"}, [7](#jah34519-bib-0007){ref-type="ref"}, [8](#jah34519-bib-0008){ref-type="ref"} In these studies, a diagnosis of plaque erosion was made by intracoronary optical coherence tomography (OCT). If the patients with plaque erosion are identified by demographic information or by simple laboratory tests, invasive procedures and procedure‐related complications may be avoided, and healthcare costs may be significantly reduced. However, demographic characteristics specific for the patients with plaque erosion are unknown. Although several groups published reports on plaque erosion,[9](#jah34519-bib-0009){ref-type="ref"}, [10](#jah34519-bib-0010){ref-type="ref"}, [11](#jah34519-bib-0011){ref-type="ref"} the study population in each report was too small or unbalanced to identify comprehensive characteristics associated with plaque erosion. The aim of the current study was to identify the predictors for plaque erosion in patients with ACS.

Methods {#jah34519-sec-0010}
=======

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Study Design and Participants {#jah34519-sec-0011}
-----------------------------

A new multi‐center longitudinal international registry was created for this study from 11 institutions in 6 countries (Table [S1](#jah34519-sup-0001){ref-type="supplementary-material"}) (Identification of Predictors for Coronary Plaque Erosion in Patients with Acute Coronary Syndrome study, <http://www.clinicaltrials.gov>: NCT03479723). Consecutive patients with ACS who had OCT imaging of the culprit lesion were eligible for the study. We included only patients who had undergone an OCT procedure, therefore this study was not "all‐comer" registry. ACS includes ST‐segment--elevation myocardial infarction (STEMI) and non--ST‐segment--elevation ACS (NSTE‐ACS) which included non--ST‐segment--elevation myocardial infarction (NSTEMI) and unstable angina pectoris. The data set consists of previously published[1](#jah34519-bib-0001){ref-type="ref"}, [2](#jah34519-bib-0002){ref-type="ref"}, [9](#jah34519-bib-0009){ref-type="ref"}, [10](#jah34519-bib-0010){ref-type="ref"} (n=695) and unpublished (n=1004) patients. Among 1699 patients, 458 patients were excluded and 1241 patients were included in the final cross‐sectional analysis (Figure [S1](#jah34519-sup-0001){ref-type="supplementary-material"}). The protocol was approved by the institutional review board at each site and written informed consent was obtained from all patients before enrollment. The definitions are described in Data [S1](#jah34519-sup-0001){ref-type="supplementary-material"}. Demographic data, medical history, laboratory data at admission, percutaneous coronary intervention procedure data, post‐percutaneous coronary intervention biomarkers, and in‐hospital death were collected. OCT imaging and angiographic imaging at index procedure were also collected. All images were de‐identified, digitally stored, and sent to Massachusetts General Hospital (Boston, MA, USA), where analysis was performed.

OCT Image Acquisition {#jah34519-sec-0012}
---------------------

A frequency‐domain OCT system (C7/C8 ILUMIEN OCT Intravascular Imaging Systems, St. Jude Medical, St. Paul, Minnesota) or a time‐domain OCT system (M2/M3 Cardiology Imaging System, St. Jude Medical, Westford, Massachusetts) was used in this study. The detailed technique of intracoronary OCT imaging was described in the previous report.[12](#jah34519-bib-0012){ref-type="ref"}

OCT Analysis {#jah34519-sec-0013}
------------

The methods of OCT analysis are summarized in Data [S1](#jah34519-sup-0001){ref-type="supplementary-material"}. Underlying plaque type in the culprit lesion was categorized into 3 groups using the previously established OCT criteria; plaque rupture, plaque erosion, calcified plaque (Figure [1](#jah34519-fig-0001){ref-type="fig"}A through [1](#jah34519-fig-0001){ref-type="fig"}C). Plaque rupture was defined by the presence of fibrous cap discontinuity with a communication between the lumen and the inner core of plaque or with a cavity formation within the plaque (Figure [1](#jah34519-fig-0001){ref-type="fig"}A).[13](#jah34519-bib-0013){ref-type="ref"}, [14](#jah34519-bib-0014){ref-type="ref"} Plaque erosion was identified by the presence of the attached thrombus overlying an intact and visualized plaque, luminal surface irregularity at the culprit lesion in the absence of thrombus, or attenuation of the underlying plaque by thrombus without superficial lipid or calcification immediately proximal or distal to the site of thrombus (Figure [1](#jah34519-fig-0001){ref-type="fig"}B).[1](#jah34519-bib-0001){ref-type="ref"}, [2](#jah34519-bib-0002){ref-type="ref"}, [11](#jah34519-bib-0011){ref-type="ref"} Calcified plaque was defined by the presence of superficial substantive calcium at the culprit site without evidence of ruptured lipid plaque (Figure [1](#jah34519-fig-0001){ref-type="fig"}C).[1](#jah34519-bib-0001){ref-type="ref"}, [2](#jah34519-bib-0002){ref-type="ref"} Culprit lesions that did not satisfy these criteria were classified as others. Tissue characterization of underlying plaque was performed using the previously established criteria.[15](#jah34519-bib-0015){ref-type="ref"}, [16](#jah34519-bib-0016){ref-type="ref"} Plaques were classified into 2 categories: (1) Fibrous plaque (homogeneous and high‐backscattering region) or (2) Lipid plaque (low signal region with a diffuse border). Lipid‐rich plaque was defined as a plaque with lipid arc \>90°. For each lipid plaque, the thinnest fibrous cap thickness and the maximal lipid arc were measured. A thin‐cap fibroatheroma was defined as plaque with a lipid arc \>90° and the thinnest part of the fibrous cap \<65 μm. Macrophage accumulations were defined as signal‐rich, distinct, or confluent punctuate regions with heterogeneous backward shadows. Calcification was recorded as well‐delineated, low backscattering heterogeneous regions. Minimal flow area was also measured for each lesion.

![Optical coherence tomography images of 3 plaque pathologies. **A**, Plaque rupture was defined by the presence of fibrous cap discontinuity with a communication between the lumen and the inner core of a plaque or with a cavity formation within the plaque. **B**, Plaque erosion was defined as a culprit plaque with an intact fibrous cap with or without attached thrombus. **C**, Calcified plaque was defined by the presence of superficial substantive calcium at the culprit site without evidence of ruptured lipid plaque. Others include spontaneous coronary artery dissection, microvascular disease, spasm, Takotsubo cardiomyopathy, myocardial infarction with non‐obstructive coronary arteries, etc. MINOCA indicates myocardial infarction with non‐obstructive coronary arteries; SCAD, spontaneous coronary artery dissection.](JAH3-8-e012322-g001){#jah34519-fig-0001}

Angiographic Analysis {#jah34519-sec-0014}
---------------------

Coronary angiograms were analyzed with the Cardiovascular Angiography Analysis System (Pie Medical Imaging B.V., Maastricht, The Netherlands). The reference diameter, minimum lumen diameter, diameter stenosis, area stenosis, and lesion length were measured. Thrombolysis in Myocardial Infarction flow grade was also evaluated for the culprit vessel.

Statistical Analysis {#jah34519-sec-0015}
--------------------

Categorical outcomes were presented as counts and proportions (%). Continuous outcomes were expressed as mean±SD. For overall between‐group comparisons, 1‐way analysis of variance or Kruskal--Wallis test was applied for continuous outcomes and Chi‐square or Fisher exact test for categorical outcomes was applied. Then post‐hoc comparisons with controlling type‐1 error by using Bonferroni correction were performed if the overall test was significant with *P*\<0.05. To identify the parameters associated with plaque erosion, univariable and multivariable logistic regression models were applied using variables that can be readily obtained in the emergency department (age, sex, medical history, medication at admission, location of ischemia, simple laboratory test (white blood cell count, hemoglobin, creatine phosphokinase) and renal function (normal renal function was defined as no history of chronic kidney disease and estimated glomerular filtration rate (eGFR) \>60 mL/min at admission). Age and hemoglobin cut‐off were determined using Youden index. Variables with a *P*\<0.10 in the univariate test were entered into the multivariable modeling. All statistical analyses were performed using JMP PRO 13.0 (SAS Institute Inc, Cary, NC).

Results {#jah34519-sec-0016}
=======

Among 1241 patients, 607 patients (48.9%) were classified as plaque rupture, 477 patients (38.4%) as plaque erosion, and 157 patients (12.7%) as calcified plaque. In 648 STEMI patients, 385 (59.4%) patients had plaque rupture and 193 (29.8%) patients had plaque erosion. In 593 NSTE‐ACS patients, 222 (37.4%) patients had plaque rupture and 284 (47.9%) patients had plaque erosion. Inter‐observer and intra‐observer variability were assessed by the evaluation of all images by 2 independent observers and by the same observer at 2 separate time points, respectively. The intra‐observer Kappa coefficients for plaque rupture, plaque erosion, and calcified plaque were 0.902, 0.922, 0.934, respectively. The inter‐observer Kappa coefficients for plaque rupture, plaque erosion, and calcified plaque were 0.878, 0.895, 0.935, respectively. Plaque erosion was significantly more frequent in NSTE‐ACS than in STEMI (47.9% versus 29.8%, *P*\<0.0002) (Figure [2](#jah34519-fig-0002){ref-type="fig"}).

![Prevalence of plaque rupture, erosion, and calcified plaque in ST‐segment--elevation myocardial infarction and non--ST‐segment--elevation acute coronary syndrome. Among 1241 patients, 648 presented with ST‐segment--elevation myocardial infarction and 593 with non--ST‐segment--elevation acute coronary syndrome. The prevalence of plaque rupture, plaque erosion, and calcified plaque was 59.4%, 29.8%, and 10.8% in ST‐segment--elevation myocardial infarction; 37.4%, 47.9%, and 14.7% in non--ST‐segment--elevation acute coronary syndrome. The prevalence of plaque erosion was significantly higher in non--ST‐segment--elevation acute coronary syndrome than in ST‐segment--elevation myocardial infarction patients (47.9% vs 29.8%, *P*=0.0002). NSTE‐ACS indicates non--ST‐segment--elevation acute coronary syndrome; STEMI,ST‐segment--elevation myocardial infarction.](JAH3-8-e012322-g002){#jah34519-fig-0002}

Patients Characteristics {#jah34519-sec-0017}
------------------------

Baseline characteristics of each group are summarized in Table [1](#jah34519-tbl-0001){ref-type="table"} and Table [S2](#jah34519-sup-0001){ref-type="supplementary-material"}. Compared with the non‐erosion group, the plaque erosion group was younger and more frequently presented with NSTE‐ACS. Hypertension, diabetes mellitus, and chronic kidney disease were significantly less frequent in the plaque erosion group. The plaque erosion group also had higher levels of hemoglobin, lower levels of inflammatory markers (high‐sensitivity C‐reactive protein and white blood cell count), and a better lipid profile. The calcified plaque group was older and had a higher prevalence of hypertension, diabetes mellitus, and chronic kidney disease, compared with the other groups. The patients in the calcified plaque group were on more medications on admission. Plaque erosion was located more frequently in the left anterior descending artery than in the right coronary artery (56.6% versus 28.5%), whereas plaque rupture was located equally in the left anterior descending and the right coronary artery (45.8% versus 40.5%). Angiographic and OCT analysis consistently showed plaque erosion patients had less complex and less vulnerable lesions, compared with patients with non‐erosion.

###### 

Patient Characteristics

                             Plaque Rupture (n=607)   Plaque Erosion (n=477)   Calcified Plaque (n=157)   *P* Value   *P* Value[a](#jah34519-note-0003){ref-type="fn"}              
  -------------------------- ------------------------ ------------------------ -------------------------- ----------- -------------------------------------------------- ---------- ----------
  Age, y                     65.3±11.9                62.8±12.3                69.9±9.2                   \<0.0001    0.0009                                             \<0.001    \<0.0001
  Men                        478 (78.8)               380 (79.7)               121 (77.1)                 0.78                                                                      
  Presentation                                                                                            \<0.0001    \<0.0001                                           0.36       \<0.0001
  STEMI                      385 (63.4)               193 (40.5)               70 (44.6)                                                                                            
  NSTE‐ACS                   222 (36.6)               284 (59.5)               87 (55.4)                                                                                            
  Hypertension               401 (66.1)               283 (59.3)               123 (78.3)                 \<0.0001    0.03                                               \<0.0001   0.003
  Dyslipidemia               442 (72.8)               329 (69.0)               114 (72.6)                 0.35                                                                      
  Diabetes mellitus          201 (33.1)               130 (27.3)               64 (40.8)                  0.004       0.04                                               0.001      0.07
  Current smoker             254 (42.0)               196 (41.4)               39 (25.0)                  0.0003      0.86                                               0.0002     0.0001
  Past smoker                106 (17.5)               106 (22.4)               52 (33.3)                  \<0.0001    0.05                                               0.006      \<0.0001
  Current+past smoker        360 (59.5)               302 (63.9)               91 (58.3)                  0.27        ···                                                ···        ···
  Previous MI                45 (7.4)                 30 (6.3)                 19 (12.1)                  0.06                                                                      
  Previous PCI               56 (9.2)                 40 (8.4)                 23 (14.7)                  0.06                                                                      
  Family history             88 (14.5)                85 (17.8)                32 (20.4)                  0.13                                                                      
  CKD                        113 (18.6)               52 (10.9)                51 (32.5)                  \<0.0001    0.0004                                             \<0.0001   0.0002
  Laboratory data                                                                                                                                                                   
  WBC, /μL                   9675±3386                9076±3270                8717±3500                  0.001       0.004                                              0.26       0.001
  Hemoglobin, g/dL           14.0±1.8                 14.2±1.7                 13.3±2.2                   \<0.0001    0.03                                               \<0.0001   0.003
  LDL‐C, mg/dL               128±42                   121±41                   108±41                     \<0.0001    0.005                                              0.001      \<0.0001
  Creatinine, mg/dL          0.97±0.79                0.90±0.72                1.65±2.41                  \<0.0001    0.16                                               0.0003     0.0008
  hs‐CRP, mg/dL              0.84±2.25                0.45±0.95                0.92±1.95                  0.003       0.0004                                             0.003      0.05
  CPK, IU/L                  518±928                  371±652                  438±935                    0.03        0.004                                              0.47       0.13
  Medication at admission                                                                                                                                                           
  Aspirin                    92 (19.7)                75 (20.3)                54 (37.2)                  \<0.0001    0.84                                               \<0.0001   \<0.0001
  P2Y12 inhibitor            38 (8.1)                 41 (11.1)                27 (18.5)                  0.002       0.14                                               0.03       0.0003
  Statin                     115 (24.6)               82 (22.2)                59 (40.7)                  \<0.0001    0.41                                               \<0.0001   0.0002
  ACE‐I/ARB                  134 (28.6)               105 (28.3)               70 (48.0)                  \<0.0001    0.92                                               \<0.0001   \<0.0001
  β‐blocker                  63 (13.5)                60 (16.2)                39 (26.7)                  0.0008      0.27                                               0.006      0.0002
  Angiographic data                                                                                                                                                                 
  Lesion location                                                              0.0002                     0.0002      0.77                                               0.007      
  LAD                        278 (45.8)               270 (56.6)               93 (59.2)                                                                                            
  LCX                        83 (13.7)                71 (14.9)                20 (12.7)                                                                                            
  RCA                        246 (40.5)               136 (28.5)               44 (28.0)                                                                                            
  QCA                                                                                                                                                                               
  RVD, mm                    2.97±0.70                2.86±0.70                2.87±0.74                  0.04        0.02                                               0.70       0.02
  MLD, mm                    0.51±0.59                0.68±0.66                0.73±0.68                  \<0.0001    \<0.0001                                           0.48       0.0005
  Diameter stenosis (%)      83.2±18.4                77.0±20.2                75.4±20.8                  \<0.0001    \<0.0001                                           0.43       \<0.0001
  Lesion length, mm          16.1±7.8                 15.1±6.5                 17.8±8.5                   0.0004      0.02                                               0.0005     0.02
  TIMI flow grade 0 to 1     242 (39.9)               119 (25.0)               37 (23.6)                  \<0.0001    \<0.0001                                           0.73       0.0002
  Multivessel disease        232 (39.1)               149 (32.5)               78 (52.0)                  \<0.0001    0.03                                               \<0.0001   0.004
  Type B2/C lesion           483 (79.6)               286 (60.0)               122 (77.7)                 \<0.0001    \<0.0001                                           \<0.0001   0.61
  OCT findings                                                                                                                                                                      
  Lipid‐rich plaque          554 (91.3)               178 (37.3)               24 (15.3)                  \<0.0001    \<0.0001                                           \<0.0001   \<0.0001
  TCFA                       373 (61.5)               33 (6.9)                 5 (3.2)                    \<0.0001    \<0.0001                                           0.09       \<0.0001
  Macrophage                 486 (80.1)               263 (55.1)               43 (27.4)                  \<0.0001    \<0.0001                                           \<0.0001   \<0.0001
  Calcification              231 (38.1)               160 (33.5)               158 (100)                  \<0.0001    0.12                                               \<0.0001   \<0.0001
  Minimum flow area, mm^2^   1.38±1.01                1.43±1.34                1.78±1.43                  \<0.0001    0.51                                               \<0.0001   \<0.0001
  Minimum FCT, μm            69±33                    121±65                   115±81                     \<0.0001    \<0.0001                                           0.18       0.0007
  Max lipid arc, degree      308±64                   276±80                   273±78                     \<0.0001    \<0.0001                                           0.84       0.03

ACE‐I indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CAD, coronary artery disease; CKD, chronic kidney disease; CP, calcified plaque; CPK, creatine phosphokinase; FCT, fibrous cap thickness; hs‐CRP, high‐sensitivity C‐reactive protein; LAD, left anterior descending artery; LCX, left circumflex artery; LDL‐C, low‐density lipoprotein cholesterol; MI, myocardial infarction; MLD, minimum lumen diameter; NSTE‐ACS, non--ST‐segment--elevation acute coronary syndrome; PCI, percutaneous coronary intervention; PE, plaque erosion; QCA, quantitative coronary angiography; PR, plaque rupture; RCA, right coronary artery; RVD, reference vessel diameter; STEMI, ST‐segment--elevation myocardial infarction; TCFA, thin‐cap fibroatheroma; TIMI, Thrombolysis in Myocardial Infarction; WBC, white blood cell count.

*P*\<0.017 was considered significant.

John Wiley & Sons, Ltd

Procedural detail, clinical course, and in‐hospital outcome are shown in Table [S3](#jah34519-sup-0001){ref-type="supplementary-material"}. Thrombectomy and stenting were more frequently performed in the plaque rupture group than in the plaque erosion group. There was no significant difference in in‐hospital outcome between the plaque erosion and the non‐erosion group except lower level of post‐procedure peak creatine phosphokinase in the erosion group (1264±1901 versus 1973±2332, *P*\<0.001).

STEMI and NSTE‐ACS in Plaque Erosion {#jah34519-sec-0018}
------------------------------------

When the erosion patients were divided based on clinical presentation, those with STEMI were more frequently smokers, had higher levels of serum low‐density lipoproteins, and were on fewer medications (aspirin, P2Y12 inhibitors, statin, angiotensin‐converting enzyme inhibitor/ARB, β‐blocker) on admission than those with NSTE‐ACS (Table [S4](#jah34519-sup-0001){ref-type="supplementary-material"}).

Predictors of Plaque Erosion {#jah34519-sec-0019}
----------------------------

Age cut‐off \<68 years, hemoglobin cut‐off \<15.0 g/dL were determined to maximize the area under the receiver operating characteristic (ROC) curve. As shown in Table [2](#jah34519-tbl-0002){ref-type="table"}, age \<68 years (odds ratio \[OR\]: 1.56, 95% CI; 1.16--2.09, *P*=0.003), anterior ischemia (OR: 1.41, 95% CI: 1.06--1.86, *P*=0.02), no diabetes mellitus (OR: 1.47, 95% CI: 1.08--2.01, *P*=0.01), hemoglobin \>15.0 g/dL (OR: 1.48, 95% CI: 1.09--2.01, *P*=0.01), and normal renal function (OR: 1.97, 95% CI: 1.32--2.95, *P*=0.0009) were found to be the independent parameters associated with plaque erosion. When all 5 parameters are present in a patient with NSTE‐ACS, the probability of plaque erosion increased to 73.1% (Figure [3](#jah34519-fig-0003){ref-type="fig"}). When all 5 conditions were present in NSTE‐ACS patients, the odds ratio of plaque erosion was 3.40 (95% CI: 1.39--8.29, *P*=0.007). A 1000 bootstrap‐samples based estimation for the probability of plaque erosion was conducted. The estimated probabilities are within the initial estimates (Table [S5](#jah34519-sup-0001){ref-type="supplementary-material"}).

###### 

Clinical and Laboratory Predictors of Plaque Erosion

  Variables                Unadjusted   Adjusted                                        
  ------------------------ ------------ -------------- ---------- ------ -------------- --------
  Age \<68 y               1.65         1.31 to 2.08   \<0.0001   1.56   1.16 to 2.09   0.003
  Anterior ischemia        1.38         1.10 to 1.74   0.006      1.41   1.06 to 1.86   0.02
  No DM                    1.42         1.10 to 1.82   0.006      1.47   1.08 to 2.01   0.01
  Hemoglobin \>15.0 g/dL   1.67         1.25 to 2.34   0.0006     1.48   1.09 to 2.01   0.01
  Normal renal function    2.23         1.60 to 3.13   \<0.0001   1.97   1.32 to 2.95   0.0009
  No hypertension          1.50         1.18 to 1.90   0.0009     1.26   0.94 to 1.68   0.13
  Statin                   0.72         0.53 to 0.97   0.03       1.21   0.88 to 1.69   0.24

DM indicates diabetes mellitus; OR, odds ratio.

John Wiley & Sons, Ltd

![Probability of plaque erosion. When all 5 parameters are present in a patient with non--ST‐segment--elevation acute coronary syndrome, the probability of plaque erosion increased to 73.1%. When a patient with non--ST‐segment--elevation acute coronary syndrome has all 5 parameters, the odd ratio increases to 3.40. DM indicates diabetes mellitus.](JAH3-8-e012322-g003){#jah34519-fig-0003}

Discussion {#jah34519-sec-0020}
==========

This is an international collaborative work that includes \>1200 patients with both STEMI and NSTE‐ACS from 11 institutions in 6 countries to identify parameters associated with plaque erosion. Plaque erosion was more frequent in NSTE‐ACS than in STEMI. Five parameters associated with plaque erosion are identified: (1) Age \<68 years, (2) anterior ischemia, (3) no diabetes mellitus, (4) hemoglobin \>15.0 g/dL, and (5) normal renal function. When all these 5 conditions are present in a patient with NSTE‐ACS, the probability of plaque erosion increases up to 73%.

Traditional Coronary Risk Factors in Plaque Erosion {#jah34519-sec-0021}
---------------------------------------------------

Some of the conventional risk factors for coronary artery disease (older age, diabetes mellitus, dyslipidemia, chronic kidney disease, hypertension) were less frequent in plaque erosion, while younger age, no diabetes mellitus, and normal renal function were associated with plaque erosion in the current study. In addition, high‐sensitivity C‐reactive protein and white blood cell count were also significantly lower in the erosion patients. OCT analysis also demonstrated significantly lower levels of plaque vulnerability (lipid‐rich plaque, thin‐cap fibroatheroma, and macrophage). Taken together, all these data suggest that plaque erosion has a distinctly different pathobiology compared with plaque rupture. Previous pathology studies reported that the characteristics of plaque erosion, which include thrombus over less atherosclerotic and less vulnerable lesions without disruption of plaque structure and absence of endothelial cell layer.[3](#jah34519-bib-0003){ref-type="ref"}, [17](#jah34519-bib-0017){ref-type="ref"}, [18](#jah34519-bib-0018){ref-type="ref"} However, the underlying mechanism of local thrombosis remains unclear. A "2‐hit scheme" was proposed for the pathogenesis of plaque erosion.[19](#jah34519-bib-0019){ref-type="ref"}, [20](#jah34519-bib-0020){ref-type="ref"} The "first‐hit" is chronic endothelial activation, propensity to slough, and impaired ability to repair the damaged endothelium. Disturbed flow was suspected to be the etiology, leading to activation of endothelial Toll‐like receptor 2. The "second‐hit" is recruitment of neutrophils via Toll‐like receptor 2 and subsequent formation of neutrophil extracellular traps, as well as local production of chemo‐attractants, thrombin, and fibrin, which further entrap platelets and lead to thrombus formation. This process is independent from pan‐vascular chronic inflammation that lead to atherosclerosis, therefore plaque erosion can occur in younger patients with less atherosclerosis.

Local Fluid Dynamics in Plaque Erosion {#jah34519-sec-0022}
--------------------------------------

Interestingly, high hemoglobin level was found to be a strong factor associated with plaque erosion. The changes of hemoglobin level over time were not collected. Therefore, a causal relationship cannot be established. However, several studies reported hemoconcentration was the risk factor for myocardial infarction.[21](#jah34519-bib-0021){ref-type="ref"} Hemoconcentration can increase blood viscosity, resulting in elevation of local endothelial shear stress. High shear condition activates both platelets and coagulation factors.[22](#jah34519-bib-0022){ref-type="ref"}, [23](#jah34519-bib-0023){ref-type="ref"} It was recently reported that high endothelial shear stress was associated with the thrombus in plaque erosion patients.[24](#jah34519-bib-0024){ref-type="ref"} Therefore, high hemoglobin levels attributable to several systemic condition may contribute to formation of occlusive thrombus in plaque erosion. In addition, plaque erosion was more frequently observed in the left anterior descending artery with anterior ischemia than in the right coronary artery or circumflex. The left anterior descending artery has more side branches than other vessels. The presence of side branches affects the conditions of local flow dynamics and distribution of endothelial shear stress,[25](#jah34519-bib-0025){ref-type="ref"} which may play a key role in pathogenesis of erosion.

STEMI and NSTE‐ACS in Plaque Erosion {#jah34519-sec-0023}
------------------------------------

In the current study, 41% of plaque erosion patients presented with STEMI and the remaining 59% of patients presented with NSTE‐ACS. Because of relatively preserved vascular structure, plaque erosion may be prone to develop non‐occlusive thrombus or occlusive thrombus that may be easily embolized distally. Several differences were noted between these 2 groups: the erosion patients with STEMI were more frequently smokers, had higher levels of serum low‐density lipoproteins, and took fewer medications on admission than those with NSTE‐ACS (Table [S4](#jah34519-sup-0001){ref-type="supplementary-material"}). The medications might have protected these patients from persistent occlusive thrombus formation. In addition, the smoking rate was significantly higher in plaque erosion patients with STEMI. Several previous studies reported that plaque erosion is associated with smoking.[11](#jah34519-bib-0011){ref-type="ref"}, [17](#jah34519-bib-0017){ref-type="ref"}, [18](#jah34519-bib-0018){ref-type="ref"} Smoking promotes activation of both platelets and clotting factors.[26](#jah34519-bib-0026){ref-type="ref"}, [27](#jah34519-bib-0027){ref-type="ref"} In addition, smoking causes endothelial damage[28](#jah34519-bib-0028){ref-type="ref"} as well as activation of Rho‐kinase,[29](#jah34519-bib-0029){ref-type="ref"} which leads to vascular hyperconstriction or vasospasm.

Clinical Significance of Predictors of Plaque Erosion {#jah34519-sec-0024}
-----------------------------------------------------

This study included only patients who had OCT imaging, therefore the result might not represent a general ACS population. Taken together, however, the current study suggests that, contrary to atherosclerotic lesions with underlying chronic inflammatory processes, plaque erosion might be the result of a combination of several "non‐traditional" factors including endothelial, vasomotion, fluid dynamic, and systemic effects (Figure [4](#jah34519-fig-0004){ref-type="fig"}). Thus, the optimal management for plaque erosion might be different from the traditional treatment of plaque rupture. In the EROSION (Effective Anti‐Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography‐Based Management in Plaque Erosion) study, we demonstrated the feasibility and safety of anti‐thrombotic therapy without stenting in patients with ACS caused by plaque erosion.[6](#jah34519-bib-0006){ref-type="ref"} We also reported a further decrease in thrombus volume between 1 month and 1 year, and a majority of patients with plaque erosion who were managed with aspirin and ticagrelor without stenting remained free of major adverse cardiac events up to 1 year.[30](#jah34519-bib-0030){ref-type="ref"} These results suggest that a tailored approach based on the underlying pathobiology of ACS may be warranted. Ultimately, whereas emergency invasive procedure with primary percutaneous coronary intervention is the standard of care for the patients with STEMI, those with NSTE‐ACS can often be stabilized with anti‐thrombotic therapy. Identification of a subset of NSTE‐ACS patients with high probability of plaque erosion may facilitate an early triage of the patients and provide an opportunity for tailored therapy.

![Pathogenesis of plaque erosion. Plaque erosion might be the result of a combination of several "non‐traditional" factors; endothelial factors, vasomotion factors, fluid dynamics factors, and systemic factors. ACS indicates acute coronary syndromes; LAD, left anterior descending artery; NETs, neutrophil extracellular traps.](JAH3-8-e012322-g004){#jah34519-fig-0004}

A different approach will be needed not only for the management after ACS, but also for prevention. In the EROSION study, all patients were treated with dual anti‐platelet therapy for 1 year.[30](#jah34519-bib-0030){ref-type="ref"}, [31](#jah34519-bib-0031){ref-type="ref"} Anti‐thrombotic therapy should be the mainstay for plaque erosion patients without stenting. However, optimal duration/choice of medications remains unknown. The restoration of endothelial function should also be considered. Cessation of smoking could be particularly important.

Study Limitations {#jah34519-sec-0025}
-----------------

This study has several limitations. First, only patients who had undergone an OCT procedure were included, and the decision to perform OCT was left at the discretion of each operator. Therefore, true denominator is unknown and the inherent selection bias cannot be excluded. However, investigators in participating institutions have extensive experience with OCT and OCT is routinely being performed in almost all comers. Second, since this was not a prospective study, there is the possibility of unmeasured confounders. Third, although data were collected from 11 institutions including 3 in Europe and 1 in the United States, the majority of patients were Asians. Fourth, no biomarkers were measured. If biomarkers specific for plaque erosion are discovered, it may significantly increase the accuracy of non‐invasive diagnosis of plaque erosion. Fifth, it can indeed be difficult to make a diagnosis of plaque erosion in the presence of large thrombus burden. Aspiration thrombectomy was allowed, but the cases with balloon angioplasty were excluded to avoid iatrogenic damage to the vessel wall including plaque rupture. The majority of plaque ruptures are associated with superficial lipid and an emptied cavity. Those cases with large residual thrombus after thrombectomy or the cases with unclear diagnosis were excluded.

Conclusions {#jah34519-sec-0026}
===========

Plaque erosion was more frequent in NSTE‐ACS than in STEMI. Five parameters associated with plaque erosion have been identified; younger age, anterior ischemia, no diabetes mellitus, normal renal function, and higher hemoglobin levels. These parameters might be useful for identification of patients with plaque erosion for possible tailored therapy based on underlying pathobiology of ACS. The results of this exploratory analysis need to be confirmed in large scale prospective clinical studies.
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